Long-Term Follow-up of HIV Positive Asymptomatic Patients Having Received Cyclosporin A

  • Rafaël Levy
  • Jean-Philippe Jais
  • Jean-Marc Tourani
  • Philippe Even
  • Jean-Marie Andrieu
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 374)


The data of the 27 asymptomatic HIV-1 seropositive patients with CD4 + cell count between 300 and 600/µl treated by Cyclosporin A (CSA) (7.5 mg/kg/day) in our institution between october 1985 and 1987 were rewiewed in October 1993. Hemoglobin concentration, platelet count, total lymphocytes, CD4+ and CD8+ cell counts and serum core protein p24 antigenemia, as well as creatininemia measured before CSA onset, at CSA cessation and twice a year were recorded as well as clinical signs and CSA toxicities. In October 1993 median duration of CSA treatment was 11 months, median follow-up after CSA cessation was 45 months and median total follow-up was 67 months. Toxicities of CSA were those commonly encountered in other pathologies. Under CSA no patient progressed toward clinical AIDS (1987 definition). The mean CD4+ cell count of the 27 patients remained unchanged (gain of 1 cell/year) under CSA treatment, while it decreased at a rate of 50 cells/year after CSA cessation (p<0,005). On the other hand CSAtreatment had no significant impact on the evolution of total lymphocyte count, CD8+ cell counts, and P24 antigenémia.


Human Immunodeficiency Virus Human Immunodeficiency Virus Type Human Immunodeficiency Virus Disease Total Lymphocyte Count Immunosuppressive Drug Cyclosporin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Andrieu JM, Even P, Venet A. AIDS and related syndromes as a viral-induced auto-immune disease of the immune system: an anti-MHCII disorder; therapeutic implications. AIDS Res 1986;2:163–174.PubMedCrossRefGoogle Scholar
  2. 2.
    Andrieu JM, Even P, Tourani JM et al. Effects of cyclosporin on T-cell subset in human immunodeficiency virus disease. Clin Immunol Immunopathol 1988;46:181–198.13.CrossRefGoogle Scholar
  3. 3.
    Andrieu JM, Even P, Tourani JM, Beldjord K, Audroin C. Results of a 2-year exploratory study with cyclosporin A in human immunodeficiency virus infection. Auto-immune aspects of HIV infection (JM Andrieu, JF Bach, P Even Eds). International congress and symposium series N 41, Royal Society of Medicine Services. London New-York 1988.Google Scholar
  4. 4.
    Aboulker JP, Andrieu JM, Gastaud JA et al. Two month double blind placebo controlled trial of cyclosporin in HIV asymptomatic subjects. V international conference on AIDS 1989; p402 (Abst).Google Scholar
  5. 5.
    Concorde Coordinating Committee. Concorde MRC/ANRS randomised double blind controlled trial of immediate and deferred Zidovudine in symptom-free HIV infection. Lancet 1994;343:871–880.CrossRefGoogle Scholar
  6. 6.
    Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993;262:1011–1018.PubMedCrossRefGoogle Scholar
  7. 7.
    Malahingam M, Peakman M, Davies ET, Ozniak A, Mac Manus JJ, Vergnani D T cell activation and disease severity in HIV infection. Clin Exp Immunol 1993;93:337–343.CrossRefGoogle Scholar
  8. 8.
    Fahey JL, Taylor JMG, Detels R et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166–172.PubMedCrossRefGoogle Scholar
  9. 9.
    Lifson AR, Hessol NA, Buchbinder SP, O’Malley PM, Barnhardt L, Segal M, Katz MH, Holmberg SD. Serum ß2-microglobulin and prediction of progression to AIDS in HIV infection. Lancet 1992;339:1436–1440.PubMedCrossRefGoogle Scholar
  10. 10.
    Simmonds P, Beatson D, Cuthbert RJG et al. Determinants of HIV disease progression; six year longitudinal study in the Edimburgh haemophilia/HIV cohort. Lancet 1991;338:1159–163.PubMedCrossRefGoogle Scholar
  11. 11.
    Zack JA, Arrigo SJ, Weitsaman Sh, GO AS, Haislip A. Chen ISY. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213–222.PubMedCrossRefGoogle Scholar
  12. 12.
    Bukringsky MI, Stanwick JL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir for HIV-1 infection. Science 1991;254:423–427.CrossRefGoogle Scholar
  13. 13.
    Gougeon ML, Olivier R, Garcia S, Guetard D, Dragic T, Dauguet C, Montagnier L. Mise en évidence d’un processus d’engagement vers la mort cellulaire par apoptose dans les lymphocytes de patients infectés par le VIH. CR Acad Sci Paris 1991;312:529–537.Google Scholar
  14. 14.
    Groux H, Torpier G, Monté D, Mouton Y, Capron A, Ameisen JC. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992;175:331–340.PubMedCrossRefGoogle Scholar
  15. 15.
    Karpas A, Lowdell M, Jacobson SK, Hill F. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. Proc Natl Acad Sci USA 1992;89:8531–8555.CrossRefGoogle Scholar
  16. 16.
    Lu W, Salerno-Goncalves R, Yan J, Doré S, Han DS, Andrieu JM. Glucocorticoides rescue CD4+ lymphocytes from activation-induced apoptosis triggered by HIV-1: implication for pathogenesis and therapy. AIDS 1995;9:35–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Franke EK, Yuan HEH, Luban J. Spenfic incorporation of cyclophilin A into HIV-1 virions. Nature 1994;372:359–362.PubMedCrossRefGoogle Scholar
  18. 18.
    Thall M, Bukovsky A, Kondo I, Rosewirth B, Walsh C, Sodroski J, Gottlinger HG. Functional association of Cyclophillin A with HIV-1 virions. Nature 1994;372:363–365.CrossRefGoogle Scholar
  19. 19.
    Schwarz A, Offerman G, Keller F, Bennhold I, L’Age Stehr J, Krause PH, Mihatsch MJ. The effect of cyclosporin on the progression of human imunodeficiency virus type 1 infection transmitted by transplatnation. Data on four cases and review of the literature. Transplantation 1993;55:95–103.PubMedCrossRefGoogle Scholar
  20. 20.
    Andrieu JM, Lu W. Viroimmunopathogenesis of HIV disease. Implications for therapy. Immunology today 1995;16:5–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Rafaël Levy
    • 1
    • 2
  • Jean-Philippe Jais
    • 1
    • 2
  • Jean-Marc Tourani
    • 1
    • 2
  • Philippe Even
    • 1
    • 2
  • Jean-Marie Andrieu
    • 1
    • 2
  1. 1.Département de Médecine InterneHôpital Laennec Faculté NeckerParisFrance
  2. 2.Département de BiostatistiqueHôpital Necker Faculté NeckerParisFrance

Personalised recommendations